Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Revenue (2016 - 2025)

Collegium Pharmaceutical has reported Revenue over the past 10 years, most recently at $205.4 million for Q4 2025.

  • Quarterly results put Revenue at $205.4 million for Q4 2025, up 12.92% from a year ago — trailing twelve months through Dec 2025 was $780.6 million (up 62.58% YoY), and the annual figure for FY2025 was $780.6 million, up 23.62%.
  • Revenue for Q4 2025 was $205.4 million at Collegium Pharmaceutical, down from $209.4 million in the prior quarter.
  • Over the last five years, Revenue for COLL hit a ceiling of $209.4 million in Q3 2025 and a floor of $3.6 million in Q1 2022.
  • Median Revenue over the past 5 years was $136.1 million (2023), compared with a mean of $125.0 million.
  • Biggest five-year swings in Revenue: tumbled 95.86% in 2022 and later skyrocketed 3882.59% in 2023.
  • Collegium Pharmaceutical's Revenue stood at $38.3 million in 2021, then soared by 238.18% to $129.6 million in 2022, then increased by 15.53% to $149.7 million in 2023, then rose by 21.51% to $181.9 million in 2024, then grew by 12.92% to $205.4 million in 2025.
  • The last three reported values for Revenue were $205.4 million (Q4 2025), $209.4 million (Q3 2025), and $188.0 million (Q2 2025) per Business Quant data.